Allergan Inc Sample Contracts
THE ELIGIBLE SUBSIDIARIES REFERRED TO HEREIN, AS BORROWERSCredit Agreement • April 4th, 2006 • Allergan Inc • Pharmaceutical preparations • New York
EXHIBIT 10.56 FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is dated as of May 26, 2004, and entered into by and among ALLERGAN, INC. (the "Company"), the banks and other financial institutions...Credit Agreement • July 29th, 2004 • Allergan Inc • Pharmaceutical preparations • New York
1.50% CONVERTIBLE SENIOR NOTES DUE 2026 INDENTUREIndenture • April 12th, 2006 • Allergan Inc • Pharmaceutical preparations • New York
EXHIBIT 10.22 [ALLERGAN LETTERHEAD] September 25, 1997 Mr. William C. Shepherd 1206 E. Balboa Boulevard Balboa, CA 92661-1420 Dear Bill, This letter agreement and release of all claims will serve to set forth all agreements and understandings relative...Termination Agreement • March 13th, 1998 • Allergan Inc • Pharmaceutical preparations • California
AGREEMENTChange in Control Agreement • March 13th, 1998 • Allergan Inc • Pharmaceutical preparations • California
Exhibit 4.4 Allergan, Inc. 5.75% Senior Notes due 2016 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 12th, 2006 • Allergan Inc • Pharmaceutical preparations • New York
Exhibit 10.1 ALLERGAN, INC. $700,000,000 1.50% Convertible Senior Notes Due 2026* Purchase AgreementPurchase Agreement • April 12th, 2006 • Allergan Inc • Pharmaceutical preparations • New York
dated as ofCredit Agreement • March 23rd, 2006 • Allergan Inc • Pharmaceutical preparations • New York
EXHIBIT 10.31 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT dated as of December 8, 2000, to the Amended and Restated Credit Agreement dated as of March 24, 1998 amending and restating the Credit Agreement dated as of May 10,...Credit Agreement • March 23rd, 2001 • Allergan Inc • Pharmaceutical preparations • New York
BY AND AMONGMerger Agreement • November 21st, 2003 • Allergan Inc • Pharmaceutical preparations • California
Exhibit 10.2 FIFTH AMENDMENT TO CREDIT AGREEMENT This FIFTH AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is dated as of March 20, 2006, and entered into by and among ALLERGAN, INC. (the "Company"), the banks and other financial institutions...Credit Agreement • March 23rd, 2006 • Allergan Inc • Pharmaceutical preparations • New York
Exhibit 4.3 ALLERGAN, INC. $641,510,000 Zero Coupon Convertible Senior Notes Due 2022 Registration Rights AgreementRegistration Rights Agreement • January 9th, 2003 • Allergan Inc • Pharmaceutical preparations • New York
EXHIBIT 10.30 AMENDED AND RESTATED CREDIT AGREEMENT AMENDED AND RESTATED CREDIT AGREEMENT dated as of March 24, 1998 amending and restating the Credit Agreement dated as of May 10, 1996 and amended as of March 5, 1998 (the "CREDIT AGREEMENT") among...Credit Agreement • March 23rd, 2001 • Allergan Inc • Pharmaceutical preparations • New York
TABLETrust Agreement • August 11th, 2000 • Allergan Inc • Pharmaceutical preparations • Missouri
EXHIBIT 4.11 THIRD AMENDMENT TO RIGHTS AGREEMENT 1. GENERAL BACKGROUND. In accordance with Section 26 of the Rights Agreement between EquiServe Trust Company, N.A., and Allergan, Inc. a Delaware corporation (the "Company"), dated January 25, 2000,...Rights Agreement • November 7th, 2005 • Allergan Inc • Pharmaceutical preparations
andRights Agreement • January 28th, 2000 • Allergan Inc • Pharmaceutical preparations • Delaware
1 EXHIBIT 4.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT is made and entered into as of November 1, 2000 by and between Allergan, Inc., a Delaware corporation ("the Company"), and Merrill Lynch & Co., Merrill Lynch, Pierce,...Registration Rights Agreement • November 1st, 2000 • Allergan Inc • Pharmaceutical preparations • New York
ALLERGAN, INC. (a Delaware corporation) ISSUER $575,270,000 Liquid Yield Option Notes(TM) due 2020 (Zero Coupon -- Subordinated)Purchase Agreement • November 1st, 2000 • Allergan Inc • Pharmaceutical preparations • New York
CONFORMED COPY FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is dated as of October 30, 2002, and entered into by and among ALLERGAN, INC. (the "Company"), the banks and other financial institutions...Credit Agreement • November 12th, 2002 • Allergan Inc • Pharmaceutical preparations • New York
Exhibit 4.3 ALLERGAN, INC. 1.50% Convertible Senior Notes Due 2026 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 12th, 2006 • Allergan Inc • Pharmaceutical preparations • New York
RECITALSRetention Agreement • March 1st, 2002 • Allergan Inc • Pharmaceutical preparations • California
Allergan, Inc.Underwriting Agreement • March 12th, 2013 • Allergan Inc • Pharmaceutical preparations • New York
Allergan, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $250,000,000 principal amount of the 1.350% Notes due 2018 of the Company (the “2018 Notes”) and an aggregate of $350,000,000 principal amount of 2.800% Notes due 2023 of the Company (the “2023 Notes” and together with the 2018 Notes, the “Securities”). Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities.
EXHIBIT 10.13 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT This FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this "Amendment") is dated as of March 16, 2007, and entered into by and among ALLERGAN, INC. (the "Company"), the...Credit Agreement • May 9th, 2007 • Allergan Inc • Pharmaceutical preparations • New York
EXHIBIT 10.33 July 20, 2001 Mr. Francis R. Tunney, Jr. 1207 Oxford Lane Newport Beach, California 92660 Dear Frank: As a follow-up to your discussions with David Pyott, and your intention to retire from Allergan on August 23, 2002, this letter...Retirement Agreement • March 1st, 2002 • Allergan Inc • Pharmaceutical preparations • California
1 EXHIBIT 4.1 INDENTURE DATED AS OF NOVEMBER 1, 2000 ---------------------------------------------------------- ALLERGAN, INC.Indenture • November 1st, 2000 • Allergan Inc • Pharmaceutical preparations • New York
Allergan, Inc. and Wells Fargo Bank, N.A. as Rights Agent Rights Agreement Dated as of April 22, 2014Rights Agreement • April 23rd, 2014 • Allergan Inc • Pharmaceutical preparations • Delaware
or made by the Company on the outstanding Common Stock in Common Stock or pursuant to a split or subdivision of the outstanding Common Stock). However, if upon acquiring beneficial ownership of one or more additional shares of Common Stock, the Existing Holder does not beneficially own 10% or more of the Common Stock then outstanding, the Existing Holder shall not be deemed to be an “Acquiring Person” for purposes of the Agreement.
BY AND BETWEEN ALLERGAN, INC. ANDTransitional Services Agreement • August 12th, 2002 • Allergan Inc • Pharmaceutical preparations • California
ALLERGAN, INC. 2003 NONEMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AWARD AGREEMENTNon-Qualified Stock Option Award Agreement • May 9th, 2007 • Allergan Inc • Pharmaceutical preparations • California
EXHIBIT 10.47 CREDIT AGREEMENTCredit Agreement • November 12th, 2002 • Allergan Inc • Pharmaceutical preparations • New York
WITNESSETH:Transfer Agent Services Agreement • November 7th, 2005 • Allergan Inc • Pharmaceutical preparations • Minnesota
EXHIBIT 10.35 CONTRIBUTION AND DISTRIBUTION AGREEMENT BY AND BETWEEN ALLERGAN, INC.Contribution and Distribution Agreement • August 12th, 2002 • Allergan Inc • Pharmaceutical preparations • California
AGREEMENT AND PLAN OF MERGER among Allergan, Inc., Groundhog Acquisition, Inc. and MAP Pharmaceuticals, Inc. Dated as of January 22, 2013Merger Agreement • January 23rd, 2013 • Allergan Inc • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER, dated as of January 22, 2013 (this “Agreement”), by and among Allergan, Inc., a Delaware corporation (“Parent”), Groundhog Acquisition, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (the “Purchaser”), and MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”). All capitalized terms used in this Agreement shall have the meanings assigned to such terms in Section 8.4 or as otherwise defined elsewhere in this Agreement.
FIRST AMENDMENT DATED 19 FEBRUARY 2007Stock Sale and Purchase Agreement • May 9th, 2007 • Allergan Inc • Pharmaceutical preparations
AGREEMENT AND PLAN OF MERGER by and among ACTAVIS PLC, AVOCADO ACQUISITION INC. and ALLERGAN, INC. dated as of November 16, 2014Merger Agreement • November 18th, 2014 • Allergan Inc • Pharmaceutical preparations • New York
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated November 16, 2014, is by and among Actavis plc, a company incorporated under the laws of Ireland (“Parent”), Avocado Acquisition Inc. a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”), and Allergan, Inc., a Delaware corporation (the “Company”). All capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Section 9.5 or as otherwise defined elsewhere in this Agreement unless the context clearly provides otherwise. Parent, Merger Sub and the Company are each sometimes referred to as a “Party” and collectively as the “Parties.”
AGREEMENTChange in Control Agreement • January 28th, 2000 • Allergan Inc • Pharmaceutical preparations • California